PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson's disease

PAAN/MIF核酸酶抑制剂可预防帕金森病中的神经退行性变

阅读:2
作者:Hyejin Park,Tae-In Kam,Hanjing Peng,Shih-Ching Chou,Amir A Mehrabani-Tabari,Jae-Jin Song,Xiling Yin,Senthilkumar S Karuppagounder,George K Umanah,A V Subba Rao,YuRee Choi,Akanksha Aggarwal,Sohyun Chang,Hyunhee Kim,Jiyoung Byun,Jun O Liu,Ted M Dawson,Valina L Dawson

Abstract

Parthanatos-associated apoptosis-inducing factor (AIF) nuclease (PAAN), also known as macrophage migration inhibitor factor (MIF), is a member of the PD-D/E(X)K nucleases that acts as a final executioner in parthanatos. PAAN's role in Parkinson's disease (PD) and whether it is amenable to chemical inhibition is not known. Here, we show that neurodegeneration induced by pathologic α-synuclein (α-syn) occurs via PAAN/MIF nuclease activity. Genetic depletion of PAAN/MIF and a mutant lacking nuclease activity prevent the loss of dopaminergic neurons and behavioral deficits in the α-syn preformed fibril (PFF) mouse model of sporadic PD. Compound screening led to the identification of PAANIB-1, a brain-penetrant PAAN/MIF nuclease inhibitor that prevents neurodegeneration induced by α-syn PFF, AAV-α-syn overexpression, or MPTP intoxication in vivo. Our findings could have broad relevance in human pathologies where parthanatos plays a role in the development of cell death inhibitors targeting the druggable PAAN/MIF nuclease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。